Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 8Lung Neoplasms 2Neuroendocrine Tumors 1Neuroendocrine Prostate Cancer 1Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Bites and Stings 1

Interventions

Carboplatin 339Cisplatin 238Paclitaxel 203Radiotherapy 194Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 140Erlotinib Hydrochloride 107Etoposide 98Magnetic Resonance Spectroscopy 92Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 71durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49Irinotecan 42atezolizumab 41Topotecan 39Radiation 39Biopsy 39Cyclophosphamide 38Standard of Care 37Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × AMG 757 × Clear all
NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

NCT04885998 2025-09-29

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Amgen

Phase 1 Completed
23 enrolled 21 charts
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡